Table 1.
Demographics and Baseline Characteristics (Safety Population)
| Characteristic | CP2L (n = 284) | CP3L (n = 119) | Total (n = 403) |
|---|---|---|---|
| Male, No. (%) | 149 (52.5) | 53 (44.5) | 202 (50.1) |
| Race, No. (%) | |||
| Asian | 62 (21.8) | 15 (12.6) | 77 (19.1) |
| Black | 16 (5.6) | 6 (5.0) | 22 (5.5) |
| Other | 20 (7.0) | 11 (9.2) | 31 (7.7) |
| White | 186 (65.5) | 87 (73.1) | 273 (67.7) |
| Age | |||
| Mean (SD), y | 51.4 (15.1) | 54.6 (13.0) | 52.4 (14.6) |
| ≥65 y, No. (%) | 63 (22.2) | 27 (22.7) | 90 (22.3) |
| ECOG performance status, No. (%) | |||
| 0 | 217 (76.4) | 85 (71.4) | 302 (74.9) |
| 1 | 65 (22.9) | 33 (27.7) | 98 (24.3) |
| 2 | 1 (0.4) | 0 | 1 (0.2) |
| Not collected | 1 (0.4) | 1 (0.8) | 2 (0.5) |
| Prior therapies, No. (%)a | |||
| 1 | 184 (64.8) | 0 | 184 (45.7) |
| 2 | 100 (35.2) | 52 (43.7) | 152 (37.7) |
| 3 | 0 | 65 (54.6) | 65 (16.1) |
| 4 | 0 | 2 (1.7) | 2 (0.5) |
| Prior interferon therapy, No. (%) | 100 (35.2) | 65 (54.6) | 165 (40.9) |
| Prior imatinib therapy, No. (%) | |||
| Intolerant | 89 (31.3) | 36 (30.3) | 125 (31.0) |
| Resistant | 195 (68.7) | 83 (69.7) | 278 (69.0) |
| Prior dasatinib therapy, No. (%) | 0 | 92 (77.3) | 92 (22.8) |
| Prior nilotinib therapy, No. (%) | 0 | 31 (26.1) | 31 (7.7) |
| Prior stem cell transplant, No. (%) | 8 (2.8) | 9 (7.6) | 17 (4.2) |
Abbreviations: CP2L, chronic‐phase second‐line; CP3L, chronic‐phase third‐line; ECOG, Eastern Cooperative Oncology Group; SD, standard deviation.
a
If a subject had received 1 or more treatment regimens with imatinib, dasatinib, nilotinib, or interferon, the subject was counted only once for the respective treatment.